KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Shiota Masaki
Eto Masatoshi
Abrégé
A method according to the present invention is a method for predicting the therapeutic effect of pharmacotherapy in the treatment of a subject with metastatic prostate cancer, wherein the pharmacotherapy includes at least one selected from among androgen deprivation therapy, androgen receptor deprivation therapy, and an anticancer drug, and said method includes a step for detecting the presence or absence of at least one single nucleotide polymorphism in the subject.
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à quatre chaînons, p.ex. taxol
A61K 31/4166 - 1,3-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p.ex. phénytoïne
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p.ex. prégnane ou progestérone substitués en position 21, p.ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes contenant des hétérocycles, p.ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
KYUSHU UNIVERSITY,NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kikuchi Sadato
Oizumi Risa
Konishi Masayoshi
Higa Mitsuru
Taniguchi Ikuo
Abrégé
Provided are: a bipolar membrane electrodialyzer which has a high electric-current efficiency and in which the cation-exchange membrane is inhibited from suffering scale deposition therein due to divalent cations; and a method for operating the bipolar membrane electrodialyzer. The method is for operating a bipolar membrane electrodialyzer configured of a bipolar membrane, a cation-exchange membrane, and an anion-exchange membrane, the method comprising using the bipolar membrane electrodialyzer to yield an acid and an alkali from brine and being characterized by conducting electrodialysis while regulating the acid solution and/or the alkali solution so as to contain a salt to be decomposed.
C02F 1/469 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par séparation électrochimique, p.ex. par électro-osmose, électrodialyse, électrophorèse
KYUSHU UNIVERSITY,NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kikuchi Sadato
Oizumi Risa
Konishi Masayoshi
Higa Mitsuru
Taniguchi Ikuo
Abrégé
Provided are a production method and a production system of calcium carbonate that utilize a calcium-containing waste and can control the alkali content in the obtained calcium carbonate. The calcium carbonate production method for producing calcium carbonate from a calcium-containing waste includes: a calcium dissolution step for adding an aqueous hydrochloric acid solution to the calcium-containing waste and dissolving calcium to prepare an aqueous solution containing calcium ions; a separation step for adjusting the hydrogen ion concentration index of the aqueous solution containing calcium ions to separate Mg, etc. from the aqueous solution; and a calcium carbonate preparation step for adding an aqueous solution containing potassium carbonate and/or sodium carbonate to the aqueous solution containing calcium ions obtained in the separation step and reacting to prepare calcium carbonate. In this calcium carbonate production method (system), in the calcium carbonate preparation step, the rate of the addition of the aqueous solution containing potassium carbonate and/or sodium carbonate is controlled so as to adjust κ, which is represented by a specific formula, to 3000 or less.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Hirai, Go
Matsunaga, Naoya
Yoritate, Makoto
Ohdo, Shigehiro
Kondo, Hirosato
Abrégé
The present invention provides candidate molecules for constituent components of various lipid nanoparticles. The present invention pertains to a C-glycoside glycolipid compound represented by formula (I) or formula (II), a lipid nanoparticle containing the same, and a pharmaceutical composition containing the lipid nanoparticles, particularly a vaccine.
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
C07H 17/04 - Radicaux hétérocycliques contenant uniquement des atomes d'oxygène comme hétéro-atomes du cycle
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation utilisant la micro-encapsulation, p.ex. utilisant des vésicules liposomiques
5.
METHOD FOR RECYCLING HYDROPHOBIC DEEP EUTECTIC SOLVENT AND NICKEL LEACHING METHOD
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
TOYOTA TSUSHO CORPORATION (Japon)
TOYOTA JIDOSHA KABUSHIKI KAISHA (Japon)
Inventeur(s)
Yamamoto, Yuji
Goto, Masahiro
Hanada, Takafumi
Moriyama, Takeru
Procter, Momoko
Abrégé
Provided is a method for enabling recovery of metal element leaching capacity of a deep eutectic solvent used for leaching a metal element from an ore containing the metal element. A method for recycling a hydrophobic deep eutectic solvent disclosed here includes: preparing a hydrophobic deep eutectic solvent used for leaching a metal element from an ore containing the metal element; and bringing the hydrophobic deep eutectic solvent and hydrochloric acid into contact with each other. In the hydrophobic deep eutectic solvent, a hydrogen bond donor is a carboxy group-containing compound, and a hydrogen bond acceptor is chloride salt. The amount of use of the hydrochloric acid is such that hydrogen chloride is 1 mole or more with respect to 1 mole of the hydrogen bond acceptor.
C22B 3/14 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés par lixiviation dans des solutions inorganiques alcalines contenant de l'ammoniaque ou des sels d'ammonium
C22B 3/16 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés par lixiviation dans des solutions organiques
6.
PROTEIN, POLYNUCLEOTIDE, EXPRESSION VECTOR, TRANSFORMANT, PLASMALOGEN-CONTAINING COMPOSITION, AND METHOD FOR PRODUCING PLASMALOGEN
INSTITUTE OF RHEOLOGICAL FUNCTION OF FOOD CO., LTD. (Japon)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Fujino Takehiko
Mawatari Shiro
Doi Katsumi
Honsho Masanori
Abrégé
This protein comprises an amino acid sequence selected from the group consisting of amino acid sequences (a), (b), (c) and (d) and has a plasmalogen synthesis activity in a bacterium that expresses the protein. (a) The amino acid sequence represented by SEQ ID NO:1; (b) an amino acid sequence which has 80% or higher sequence identity with the amino acid sequence represented by SEQ ID NO:1; (c) the amino acid sequence represented by SEQ ID NO:2; and (d) an amino acid sequence which has 80% or higher sequence identity with the amino acid sequence represented by SEQ ID NO:2.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 1/15 - Champignons; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - Levures; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12P 7/64 - Graisses; Huiles; Cires de type ester; Acides gras supérieurs, c. à d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyle; Huiles ou graisses oxydées
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Sakuma, Shinya
Yamanishi, Yoko
Huang, Wenjing
Kimura, Niko
Sugano, Shigeo
Suzuki, Hayato
Abrégé
Provided are an introduction device and a delivery method that are applicable to various types of cells and capable of delivering a target substance, even including a large molecule, to cells at a high efficiency. The introduction device and the method for delivering a target substance to cells using the introduction device, said introduction device being equipped with a bubble generation unit 20, a counter electrode 40 and a power supply unit 50 connected respectively to the bubble generation unit and the counter electrode. The bubble generation unit 50 comprises a core material 21 made of a conductive material and forming an active electrode, and a tubular member 22 made of an insulating material and extending along the core material to cover around the core material. The tip of the tubular member 22 is substantially on the same plane as the tip of the core material 21, or extends beyond the tip of the core material 21. The bubble generation unit 20 is configured to generate bubbles from the tip of the bubble generation unit 20 when a voltage is applied to the active electrode from the power supply unit in the state where the tip of the bubble generation unit 20 and the counter electrode 40 are in contact with a liquid containing the cells and the target substance.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Ohkawa, Yasuyuki
Harada, Akihito
Oki, Shinya
Abrégé
A nucleic acid fragment including a polymerase binding sequence and a transposase binding sequence, in which the polymerase binding sequence or the transposase binding sequence contains a caged nucleotide residue; a specific binding substance; a method for binding a polymerase or a transposase to the nucleic acid fragment; a method for inserting the nucleic acid fragment in a vicinity of a binding region of a DNA-binding protein bound to a DNA molecule; and a method for gene-amplifying the DNA molecule into which the nucleic acid fragment is inserted are provided.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (Japon)
OSAKA UNIVERSITY (Japon)
KYOTO UNIVERSITY (Japon)
SHINSHU UNIVERSITY (Japon)
Inventeur(s)
Nishida, Motohiro
Nishiyama, Kazuhiro
Kato, Yuri
Nishimura, Akiyuki
Nagata, Ryu
Mori, Yasuo
Nakagawa, Yasuaki
Kuwahara, Koichiro
Abrégé
Provided is a drug for preventing or treating heart failure, that is effective and that does not have a blood pressure lowering effect. The present invention pertains to: a pharmaceutical composition for preventing or treating heart failure or skeletal muscle failure, the pharmaceutical composition containing a TRPC3/6/7 channel activator; and a related screening method.
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61P 9/04 - Agents inotropes, c. à d. stimulants de la contraction cardiaque; Médicaments pour le traitement de l'insuffisance cardiaque
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
C07D 401/00 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
10.
BORON-CONTAINING COMPOUND, AND LIGHT-EMITTING MATERIAL AND LIGHT-EMITTING ELEMENT USING SAME
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
NIPPON SODA CO., LTD. (Japon)
Inventeur(s)
Yasuda Takuma
Min Hyukgi
Kim Hyung Jong
Tanaka Katsunori
Abrégé
The present invention relates to a compound represented by formula (I) (in the formula, R1is a C1-4 alkyl group or the like, and A1and A2are each independently a group, etc. represented by formula (II), in which R2and R3 are each independently a hydrogen atom, a C1-4 alkyl group, or the like, and * is a bonded section), a light-emitting material containing said compound, and a light-emitting element containing said light-emitting material.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Tsuji, Takeshi
Fujikawa, Shigenori
Abrégé
An object of the present invention is to provide an apparatus for injecting carbon dioxide into underground capable of capturing carbon dioxide from the atmosphere and injecting it into underground in a harmless state and at a low cost, the apparatus including: a capturing unit configured to concentrate carbon dioxide directly from the atmosphere and capture concentrated carbon dioxide as a mixture gas; and an injection well connected to the capturing unit for pressurizing the mixture gas and injecting the mixture gas into an underground reservoir, in which the capturing unit adjusts a proportion of carbon dioxide in the mixture gas to 25% by volume or more.
E21B 41/00 - Matériel ou accessoires non couverts par les groupes
B01D 53/22 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Anada, Takahisa
Tanaka, Masaru
Kobayashi, Shingo
Kawahara, Michiharu
Abrégé
The present invention provides a compound for treating or preventing reduced intracellular ATP levels. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition that contains the compound or the pharmaceutically acceptable salt or solvate thereof. [In the formula, X and Y are the same or different and are each selected from among substituent group A, which is groups represented by formula 1: -O-R1 (in the formula, R1 is selected from among hydrogen, C1–8 alkyl groups, C1–3 alkyl aryl groups, CH3OCH2-, CH3OCH2CH2-, ester groups, phenyl groups, pyridyl groups, benzyl groups, indolyl groups, and naphthyl groups, and any aromatic rings or heterocyclic rings may be substituted with one to three functional groups) when the atom connected to the phosphorus atom is O, or substituent group B, which is groups represented by formula 2: -R2-R3 (in the formula, R2 is a residue generally described as an amino carboxylic acid, and R3 is a substituent bonded to the carboxylic acid portion of the amino carboxylic acid of R2) when the atom connected to the phosphorus atom is N.]
C07H 19/207 - Radicaux purine avec le radical saccharide estérifié par des acides phosphoriques ou polyphosphoriques les acides phosphoriques ou polyphosphoriques étant estérifiés par un autre composé hydroxylique, p.ex. les dinucléotides de la flavine-adénine ou de la nicotinamide-adénine
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p.ex. adénosine, acide adénylique
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07F 9/6558 - Composés hétérocycliques, p.ex. contenant du phosphore comme hétéro-atome du cycle contenant au moins deux hétérocycles différents ou différemment substitués ni condensés entre eux ni condensés avec un carbocycle commun ou un système carbocyclique commun
13.
RUTHENIUM COMPLEX, METHOD FOR PRODUCING SAME, CATALYST COMPOSITION, OXIDATION METHOD AND METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Uchida Tatsuya
Doiuchi Daiki
Shimoda Nanako
Abrégé
123411 represents triphenyl phosphine, pyridine, imidazole, dimethyl sulfoxide or water; X represents a monovalent group that is obtained by removing a hydrogen atom from a carboxyl group of a carboxylic acid; X- represents an anion of the carboxylic acid; and n represents 1 or 2.
C07C 45/28 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogène; Préparation des chélates de ces composés par oxydation de restes —CHx
C07C 49/403 - Composés saturés comportant un groupe cétone faisant partie d'un cycle d'un cycle à six chaînons
C07C 67/29 - Préparation d'esters d'acides carboxyliques par modification de la partie hydroxyle de l'ester sans introduction d'un groupe ester par introduction de groupes fonctionnels contenant de l'oxygène
C07C 69/14 - Esters d'acide acétique de composés monohydroxylés
C07C 69/16 - Esters d'acide acétique de composés dihydroxylés
C07C 201/12 - Préparation de composés nitrés par des réactions ne créant pas de groupes nitro
C07C 205/57 - Composés contenant des groupes nitro liés à un squelette carboné le squelette carboné étant substitué de plus par des groupes carboxyle ayant des groupes nitro et des groupes carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du squelette carboné
C07C 227/16 - Préparation de composés contenant des groupes amino et carboxyle liés au même squelette carboné à partir de composés contenant déjà des groupes amino et carboxyle ou leurs dérivés par des réactions n'impliquant pas les groupes amino ou carboxyle
C07C 229/08 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe amino et un seul groupe carboxyle liés au squelette carboné l'atome d'azote du groupe amino étant lié de plus à des atomes d'hydrogène
C07C 303/40 - Préparation d'esters ou d'amides d'acides sulfuriques; Préparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfoniques par des réactions n'impliquant pas la formation de groupes sulfonamide
C07C 311/19 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à des atomes d'hydrogène ou à un atome de carbone acyclique à un atome de carbone acyclique d'un radical hydrocarboné substitué par des groupes carboxyle
C07D 213/38 - Radicaux substitués par des atomes d'azote liés par des liaisons simples comportant uniquement de l'hydrogène, ou des radicaux hydrocarbonés, liés à l'atome d'azote substituant
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
HAMAMATSU PHOTONICS K.K. (Japon)
Inventeur(s)
Adachi, Chihaya
Nakanotani, Hajime
Yamanaka, Takahiko
Hara, Shigeo
Abrégé
An organic light-receiving element includes an organic light-receiving layer containing a plurality of organic semiconductor molecules. Each of the plurality of organic semiconductor molecules is a molecule in which an excited state enabling reverse intersystem crossing from a lowest excited triplet state to a lowest excited singlet state is formed in each of the plurality of organic semiconductor molecules due to irradiation with light.
H10K 30/20 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire comprenant des jonctions organiques-organiques, p. ex. des jonctions donneur-accepteur
15.
BIOMOLECULE STRUCTURE DETECTION PROBE, BIOMOLECULE STRUCTURE DETECTION KIT, AND METHOD FOR DETECTING BIOMOLECULE STRUCTURE
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Ohkawa, Yasuyuki
Tomimatsu, Kosuke
Abrégé
A biomolecule structure detection probe, wherein a specific binding substance having a specific binding activity to a biomolecule structure is linked to a labeling substance via a linker including a disulfide bond. In addition, a biomolecule structure detection kit including the biomolecule detection probe and a reagent for cleaving the disulfide bond. In addition, a biomolecule structure detection kit including a linker for linking a specific binding substance having a specific binding activity to a biomolecule structure with a labeling substance, the linker including a disulfide bond; and a labeling substance capable of being bonded to the linker; and a reagent for cleaving the disulfide bond. In addition, a method for detecting a biomolecule structure using the biomolecule structure detection probe.
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
16.
METHOD FOR DESIGNING RNA BINDING PROTEIN UTILIZING PPR MOTIF, AND USE THEREOF
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Nakamura, Takahiro
Yagi, Yusuke
Kobayashi, Keiko
Abrégé
A method for designing a protein capable of binding in an RNA base selective manner or RNA base sequence specific manner is provided. The protein of the present invention is a protein containing one or more of PPR motifs (preferably 2 to 14 PPR motifs) each consisting of a polypeptide of 30- to 38-amino acid length represented by the formula 1 (wherein Helix A is a moiety of 12-amino acid length capable of forming an α-helix structure, and is represented by the formula 2, wherein, in the formula 2, A1 to A12 independently represent an amino acid; X does not exist, or is a moiety of 1- to 9-amino acid length; Helix B is a moiety of 11- to 13-amino acid length capable of forming an α-helix structure; and L is a moiety of 2- to 7-amino acid length represented by the formula 3, wherein, in the formula 3, the amino acids are numbered “i” (−1), “ii” (−2), and so on from the C-terminus side, provided that Liii to Lvii may not exist), and combination of three amino acids A1, A4 and Lii, or combination of two amino acids A4, and Lii is a combination corresponding to a target RNA base or base sequence.
G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p.ex. relations structurelles ou fonctionnelles ou alignement de structures
G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
G16B 35/00 - TIC spécialement adaptées aux bibliothèques combinatoires in silico d’acides nucléiques, de protéines ou de peptides
G16B 20/30 - Détection de sites de liaison ou de motifs
G16B 30/10 - Alignement de séquence; Recherche d’homologie
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kobayashi Shingo
Yoshida Kento
Tanaka Masaru
Abrégé
Provided is a novel polymer compound containing a chain ether structure and exhibiting bioaffinity. The polymer compound has a polyolefin skeleton as a main chain and a structure including a chain ether structure introduced into a side chain part thereof.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Tanaka, Yoshiyuki
Hirajima, Tsuyoshi
Aoki, Yuji
Miki, Hajime
Suyantara, Gde Pandhe Wisnu
Abrégé
This flotation recovery rate prediction device, for predicting the recovery rate of a metal subject to sorting in flotation sorting in which the metal subject to sorting is separated from an ore in which a plurality of ores containing a plurality of minerals are mixed, comprises: a receiving unit for receiving a desired recovery rate of the metal subject to sorting; an acquisition unit for acquiring information representing the relationship between soluble metal ratio and mineral content, and information representing the recovery rate of the metal subject to sorting and the mineral content of each of the ores; a calculation unit for calculating, on the basis of the information representing the relationship between soluble metal ratio and mineral content and the information representing the recovery rate of the metal subject to sorting and the mineral content of each of the ores, the mixing ratio of the ores to achieve the desired recovery rate of the metal subject to sorting; and an output unit for outputting information indicating the calculated mixing ratio of the ores.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kawanishi, Eiji
Ojida, Akio
Nishida, Motohiro
Kato, Yuri
Abrégé
The present invention provides a compound for treating or preventing diseases caused by mitochondrial hyperfission.
The present invention provides a compound for treating or preventing diseases caused by mitochondrial hyperfission.
The present invention provides a compound represented by formula (1):
The present invention provides a compound for treating or preventing diseases caused by mitochondrial hyperfission.
The present invention provides a compound represented by formula (1):
wherein
R1 and R1′ are each independently hydrogen, an optionally substituted lower alkyl, an optionally substituted lower cycloalkyl, and the like; R2 is an optionally substituted lower alkyl, an optionally substituted lower cycloalkyl, and the like; R3 and R4 are each independently hydrogen, halogen, hydroxy, nitro, cyano, an optionally substituted lower alkyl, and the like; R5 and R6 are each independently an optionally substituted lower alkyl; an optionally substituted lower cycloalkyl, and the like; X is nitrogen or oxygen; Y is carbon, nitrogen or oxygen; and a broken line represents the presence or absence of a bond;
or a pharmaceutically acceptable salt, a solvate, or a prodrug thereof.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Yamamoto, Hiroaki
Katakura, Yoshinori
Abrégé
An object of the present invention is to provide a novel agent capable of activating SIRT6. A sirtuin 6 activator containing a urolithin as an active ingredient.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Anada Takahisa
Kado Yuri
Nishida Kei
Tanaka Masaru
Abrégé
The present invention provides a copolymer compound having a new property through compounding a polymer comprising a (meth)acrylic skeleton and/or a (meth)acrylamide skeleton with a structure different from the primary structure of the polymer. Provided is a polymer compound comprising a (meth)acrylic skeleton and/or a (meth)acrylamide skeleton, wherein a side chain comprising a phosphonic acid group is introduced as a part of a side chain of the polymer compound.
C08F 220/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
C08F 230/02 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et contenant du phosphore, du sélénium, du tellure ou un métal contenant du phosphore
C08L 33/04 - Homopolymères ou copolymères des esters
C08L 33/24 - Homopolymères ou copolymères des amides ou des imides
C08L 43/02 - Homopolymères ou copolymères de monomères contenant du phosphore
C09D 133/04 - Homopolymères ou copolymères d'esters
C09D 133/24 - Homopolymères ou copolymères d'amides ou d'imides
C09D 143/02 - Homopolymères ou copolymères de monomères contenant du phosphore
Kyushu University, National University Corporation (Japon)
Inventeur(s)
Yagi, Yusuke
Ohta, Masaru
Nakamura, Takahiro
Abrégé
It was found that four nuclease domain mutants have nuclease activity superior to that of a wild-type nuclease domain and are capable of enhancing genome editing efficiency in combination with various nucleic acid binding domains.
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
23.
METAL-CONTAINING ADDITIVE, CROSSLINKABLE POLYMER COMPOSITION, CROSSLINKED POLYMER MATERIAL, METAL MEMBER, AND WIRE HARNESS
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Oshiumi, Naoyuki
Hosokawa, Takehiro
Mizoguchi, Makoto
Abrégé
To provide a metal-containing additive and a crosslinkable polymer composition that each contain a β-diketonato metal complex and have excellent storage stability, and provide a crosslinked polymer material, a metal member, and a wire harness that are each produced using such a crosslinkable polymer composition. The metal-containing additive includes the β-diketonato metal complex and a primary alkyl alcohol having 4 to 30 carbon atoms. The crosslinkable polymer composition includes the metal-containing additive and an organic polymer, where the organic polymer has a substituent capable of forming ionic bonds with metal ions released by heat from the metal-containing additive.
C09D 7/63 - Adjuvants non macromoléculaires organiques
H01B 7/00 - Conducteurs ou câbles isolés caractérisés par la forme
H01B 7/28 - Protection contre les dommages provoqués par des facteurs extérieurs, p.ex. gaines ou armatures par l'humidité, la corrosion, les attaques chimiques ou les conditions atmosphériques
24.
CROSSLINKABLE POLYMER COMPOSITION, CROSSLINKED POLYMER MATERIAL, METAL MEMBER, AND WIRING HARNESS
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Oshiumi, Naoyuki
Hosokawa, Takehiro
Mizoguchi, Makoto
Abrégé
A crosslinkable polymer composition and a crosslinked polymer material including a metal member and a wiring harness. The crosslinkable polymer composition contains component A from which metal ion is released by heat, component B containing an organic polymer having a substituent capable of ionic bonding with the metal ion released from component A, and component C containing one or more acidic phosphate ester with a carbon number of 4 to 30. Assuming that the metal ion released from component A has a valence of +y and a content of the metal ion is m mol, the substituent contained in component B has a valence of −z and a content of the substituent is n mol, the acidic phosphate constituting component C has a valence of −x and a content of the acidic phosphate esters is 1 mol
A crosslinkable polymer composition and a crosslinked polymer material including a metal member and a wiring harness. The crosslinkable polymer composition contains component A from which metal ion is released by heat, component B containing an organic polymer having a substituent capable of ionic bonding with the metal ion released from component A, and component C containing one or more acidic phosphate ester with a carbon number of 4 to 30. Assuming that the metal ion released from component A has a valence of +y and a content of the metal ion is m mol, the substituent contained in component B has a valence of −z and a content of the substituent is n mol, the acidic phosphate constituting component C has a valence of −x and a content of the acidic phosphate esters is 1 mol
g≥0.1 holds for g=(m·y−l·x)/(n·z).
C09D 147/00 - Compositions de revêtement à base d'homopolymères ou de copolymères de composés possédant un ou plusieurs radicaux aliphatiques non saturés, l'un au moins contenant plusieurs liaisons doubles carbone-carbone; Compositions de revêtement à base de dérivés de tels polymères
C09D 133/08 - Homopolymères ou copolymères d'esters de l'acide acrylique
H01B 7/28 - Protection contre les dommages provoqués par des facteurs extérieurs, p.ex. gaines ou armatures par l'humidité, la corrosion, les attaques chimiques ou les conditions atmosphériques
H01B 7/29 - Protection contre les dommages provoqués par des facteurs extérieurs, p.ex. gaines ou armatures par des températures extrêmes ou par les flammes
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Katada, Sayako
Nakashima, Kinichi
Sakaki, Yusuke
Abrégé
The subject's brain neurogenesis promoter of the present invention contains miR-30a, etc. or a vector which is for expressing miR-30a, etc. in the brain nerves of young and elderly subjects. The present invention also provides an agent for improving higher nervous function, an agent for improving memory learning function, a method for promoting brain neurogenesis, a method for improving higher nervous function, and a method for improving memory learning function. In the subject's brain neurogenesis promoter, etc. of the present invention, the subject may be an elderly subject.
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
26.
COMPOSITION CONTAINING ANIONIC LONG-CHAIN LIPID TO BE USED FOR ATTENUATING SKIN BARRIER FUNCTION, AND DISPERSION CONTAINING COMPLEX COMPRISING CATIONIC LONG-CHAIN LIPID, ANIONIC LONG-CHAIN LIPID AND DRUG DISPERSED THEREIN
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
NOVIGO PHARMA, INC. (Japon)
Inventeur(s)
Toyofuku Kiyohiro
Goto Masahiro
Kitaoka Momoko
Abrégé
The present invention provides a composition to be used for attenuating skin barrier, said composition containing an anionic long-chain lipid (in particular, a long-chain fatty acid). The present invention provides a dispersion in which a complex (for example, a solid complex) comprising a cationic long-chain lipid, an anionic long-chain lipid and a drug is dispersed.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres lyophilisées
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
A61K 47/24 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p.ex. cyclométhicone ou phospholipides
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation utilisant la micro-encapsulation, p.ex. utilisant des vésicules liposomiques
27.
OPTICAL ELEMENT AND METHOD FOR PRODUCING OPTICAL ELEMENT
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Sato Hiromu
Yokoyama Shiyoshi
Abrégé
The purpose of the present invention is to provide a low-production-cost and low-loss optical element. Provided are an optical element (100) and a method for producing the optical element (100), the optical element (100) having a core (2) and a cladding comprising an undercladding (4) and an overcladding (3) on a substrate (1), wherein the core (2) includes a membrane structure (21) in at least a leading end region (31), includes a thin line structure (22) in an inner portion away from a leading end (P1) of the membrane structure (21) in a length direction, and has a stacking region (32) in which the membrane structure (21) and the thin line structure (22) overlap adjacent to each other in a thickness direction, a width (W1) at the leading end (P1) of the membrane structure (21) is wider than the width in the stacking region (32) of the thin line structure (22), and the materials of the membrane structure (21) and the thin line structure (22) included in the core (2) have substantially the same refractive index.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Yamazaki Yoshihiro
Shi Nai
Hyodo Junji
Abrégé
This composite conductive material includes: a main phase that includes a crystalline phase having a double perovskite crystalline structure; and particles that each project from the surface of the main phase and that each contain an oxide of a metal element occupying the B site of the crystalline phase.
H01M 4/86 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes inertes ayant une activité catalytique, p.ex. pour piles à combustible
H01B 1/06 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisés; Emploi de matériaux spécifiés comme conducteurs composés principalement d'autres substances non métalliques
H01B 1/08 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisés; Emploi de matériaux spécifiés comme conducteurs composés principalement d'autres substances non métalliques oxydes
H01M 8/12 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides fonctionnant à haute température, p.ex. avec un électrolyte en ZrO2 stabilisé
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Yamato Kenta
Taniguchi Masahiro
Nakatake Hirokazu
Esaki Keiichi
Kusakabe Takahiro
Abrégé
An oral vaccine composition against a porcine circovirus-related disease, the oral vaccine composition comprising a pupa or a cell of a baculovirus infectious insect that has been subjected to an infection treatment with a recombinant baculovirus into which a DNA encoding a porcine circovirus type 2 protein has been introduced and subjected to a freeze-drying treatment.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 31/20 - Antiviraux pour le traitement des virus ADN
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Miura Fumihito
Abrégé
Provided is, for example, a DNA methyltransferase that can recognize and methylate a short context other than a CG dinucleotide sequence in which endogenous methylation occurs, the short context being comparable to the CG dinucleotide sequence. The present invention pertains to a protein or the like in which some amino acid residues including the N terminal of a DNA methyltransferase of M.CviQIX or M.CviPII have been deleted, and activity of specifically recognizing a CC dinucleotide sequence and 5-methylating a cytosine residue of the 5' side in the sequence is acquired.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une transférase
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Aoki, Junki
Yamashina, Ryota
Kurazume, Ryo
Abrégé
An information processing device, for communicating with an autonomous mobile device, includes circuitry and a memory storing computer-executable instructions that cause the circuitry to execute transmitting an operation command of an operator of the autonomous mobile device to the autonomous mobile device existing in a real world and a virtual mobile device simulating the autonomous mobile device and existing in a virtual world simulating the real world, and switching from a real mode to a virtual mode when the autonomous mobile device detects an inhibitor inhibiting operability of the operator to operate the autonomous mobile device, the real mode providing the operator with sensory feedback corresponding to an autonomous movement of the autonomous mobile device in the real world, and the virtual mode providing the operator with sensory feedback corresponding to a movement according to the operation command of the virtual mobile device in the virtual world.
G05D 1/00 - Commande de la position, du cap, de l'altitude ou de l'attitude des véhicules terrestres, aquatiques, aériens ou spatiaux, p.ex. pilote automatique
G05D 1/02 - Commande de la position ou du cap par référence à un système à deux dimensions
32.
PLANT SENSOR DEVICE AND ACTIVE OPTICAL MEASUREMENT METHOD OF PLANT
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kume Atsushi
Abrégé
Provided is a plant sensor device that is capable of suppressing the influence of outside light in the surrounding environment to quantify the growth degree of a plant and obtaining a parameter related to the amount of foliage of the plant using a simple and low-cost configuration. A plant sensor device 100 comprising a light source 11 that intermittently irradiates a plant with near-infrared (NIR) light, a radiation sensor 21 that is disposed on the opposite side of the light source 11 with respect to the plant and outputs output values obtained by photoelectrical conversion of the received transmitted NIR light having transmitted through the plant, and a recording unit 31 that records the output values from the radiation sensor 21, wherein the recording unit 31 records the irradiation period and the quenching period of the near-infrared light at light source 11, and the recording unit 31 classifies the output values from the radiation sensor into (1) NIR output values during the irradiation period of the near-infrared light and (2) non-irradiation output values during the quenching period of the near-infrared light; and an active optical measurement method of plant.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Ooe, Kenichi
Ukawa, Yuichi
Nakajima, Takanori
Katakura, Yoshinori
Abrégé
The present disclosure addresses the problem of providing at least a technology for enhancing the expression of SIRT3 genes. Said problem is solved by a composition for enhancing SIRT3 gene expression, the composition containing urolithin M3 as an active ingredient.
A61K 31/366 - Lactones ayant des cycles à six chaînons, p.ex. delta-lactones
A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61P 17/16 - Médicaments pour le traitement des troubles dermatologiques Émollients ou protecteurs, p.ex. contre les radiations
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61Q 19/08 - Préparations contre le vieillissement
C12N 15/12 - Gènes codant pour des protéines animales
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Matsumura, Yasushi
Abe, Kohtaro
Kimuro, Keiji
Imabayashi, Misaki
Abrégé
The present invention addresses the problem of providing a medicine for treating cardiovascular disease associated with inflammation of the cardiovascular system related to IL-6 and/or IL-1β. The present invention relates to an IL-6 and/or IL-1β inhibitor comprising a compound represented by formula (I) (in the formula, each symbol is as described in the specification.) or a pharmaceutically acceptable salt thereof. The present invention also relates to a medicine for treating cardiovascular disease associated with inflammation of the cardiovascular system related to IL-6 and/or IL-1β that contains as an active ingredient the abovementioned compound or a pharmaceutically acceptable salt thereof.
A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p.ex. tétrazole
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
Kyushu University, National University Corporation (Japon)
Gigaphoton Inc. (Japon)
Inventeur(s)
Ikenoue, Hiroshi
Mizutani, Akira
Abrégé
A machine learning method includes acquiring image data generated from reflected light of illumination light radiated to a first region of a semiconductor film on a substrate, the first region annealed by pulse laser light, acquiring data on a measured semiconductor property of the first region, generating training data including the image data as input and the measured data as output associated with each other, and performing machine learning using a neural network based on the training data to generate a learned model.
H01L 21/67 - Appareils spécialement adaptés pour la manipulation des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide pendant leur fabrication ou leur traitement; Appareils spécialement adaptés pour la manipulation des plaquettes pendant la fabrication ou le traitement des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide ou de leurs composants
H01L 21/268 - Bombardement par des radiations ondulatoires ou corpusculaires par des radiations d'énergie élevée les radiations étant électromagnétiques, p.ex. des rayons laser
H01L 21/687 - Appareils spécialement adaptés pour la manipulation des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide pendant leur fabrication ou leur traitement; Appareils spécialement adaptés pour la manipulation des plaquettes pendant la fabrication ou le traitement des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide ou de leurs composants pour le maintien ou la préhension en utilisant des moyens mécaniques, p.ex. mandrins, pièces de serrage, pinces
NIPPON STEEL Chemical & Material Co., Ltd. (Japon)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Tada, Masashi
Kawada, Atsushi
Sagara, Yuta
Kitera, Sayuri
Yasuda, Takuma
Min, Hyukgi
Park, In Seob
Abrégé
Provided are an emission material and an organic EL device including the emission material and having high emission efficiency and a long lifetime. An organic EL device comprising light emitting layers between an anode and a cathode opposite to each other; wherein at least one of the light emitting layers contains, as a light emitting dopant, a compound in which a backbone having a specific 5-ring-fused ring structure, and a boron atom are combined, and the compound is represented by the following general formula (1).
Provided are an emission material and an organic EL device including the emission material and having high emission efficiency and a long lifetime. An organic EL device comprising light emitting layers between an anode and a cathode opposite to each other; wherein at least one of the light emitting layers contains, as a light emitting dopant, a compound in which a backbone having a specific 5-ring-fused ring structure, and a boron atom are combined, and the compound is represented by the following general formula (1).
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kondou, Takahiro
Sumikawa, Taiki
Abrégé
This vibration analysis method is a method for analyzing vibrations of a large-scale system with local strong nonlinearities, and includes a process (1) of applying the new type of complex modal analysis to an equation for a linear state variable to convert the equation to a real modal equation for lower-order modes, and correcting an effect of higher-order modes of the linear state variable from an equation for a nonlinear state variable and eliminating the modes, a process (2) of selecting secondary modes, which have a large effect on a solution of an original large-scale system, from the real modal equation for lower-order modes, and, in relation to secondary modes, which have a small effect, eliminating the modes thereof by incorporating the effect to the equation for nonlinear state variables as a correction term obtained from an approximate solution of the real modal equation for lower-order modes, and deriving the dimension reduced model, and a process (3) of calculating a frequency response by using the dimension reduced model.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Oshiumi, Naoyuki
Hosokawa, Takehiro
Mizoguchi, Makoto
Abrégé
A thermally conductive additive is excellent in thermal conductivity improvement effect and has high processability, and a thermally conductive composite material and a wire harness each contain such a thermally conductive additive. The thermally conductive additive includes an organic component and a metal-containing component, where the organic component is configured as an organic compound including a coordination part that can multidentate-coordinate to a metal, and at least one functional group bonded to the coordination part and having a conjugated π-electron system, and the organic component coordinates in the coordination part to a metal atom constituting the metal-containing component to form a coordination complex. The thermally conductive composite material includes the thermally conductive additive and a matrix material, where the thermally conductive additive is dispersed in the matrix material. The wire harness includes the thermally conductive composite material.
C07C 49/84 - Cétones comportant un groupe cétone lié à un cycle aromatique à six chaînons contenant des groupes éther, des groupes , des groupes ou des groupes
C07C 49/213 - Composés non saturés comportant des groupes cétone liés à des atomes de carbone acycliques contenant des cycles aromatiques à six chaînons
C07C 49/825 - Cétones comportant un groupe cétone lié à un cycle aromatique à six chaînons contenant des groupes hydroxyle tous les groupes hydroxyle étant liés au cycle
C07C 49/83 - Cétones comportant un groupe cétone lié à un cycle aromatique à six chaînons contenant des groupes hydroxyle polycycliques
C07C 49/14 - Acétylacétone, c. à d. pentanedione-2,4
H01B 7/00 - Conducteurs ou câbles isolés caractérisés par la forme
H01B 7/42 - Conducteurs ou câbles isolés caractérisés par la forme avec des dispositions pour la dissipation ou la conduction de la chaleur
39.
THERMALLY CONDUCTIVE FILLER, THERMALLY-CONDUCTIVE COMPOSITE MATERIAL, WIRE HARNESS, AND METHOD FOR MANUFACTURING THERMALLY CONDUCTIVE FILLER
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Oshiumi, Naoyuki
Hosokawa, Takehiro
Nakashima, Kazuo
Rachi, Hironobu
Kawakami, Takashi
Maeda, Yusaku
Mizoguchi, Makoto
Abrégé
A thermally conductive filler can exhibit high thermal conductive properties with a reduced specific gravity, a thermally-conductive composite material and a wire harness contains such a thermally conductive filler, and a method manufactures a thermally conductive filler. A thermally conductive filler contains base particles and a coating layer coating the particles, the coating layer contains a gel-like substance that is bonded to the surfaces of the base particles through chemical bonding and coats the surfaces of the base particles, and a thermally-conductive substance that is dispersed in the layer of the gel-like substance and has a higher thermal conductivity and a larger specific gravity than the base particles and the gel-like substance. Also, a thermally-conductive composite material is obtained by dispersing the thermally conductive filler in a matrix material. Furthermore, a wire harness contains the thermally-conductive composite material.
C03C 17/32 - Traitement de surface du verre, p.ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement par des matières organiques avec des résines synthétiques ou naturelles
C03C 17/00 - Traitement de surface du verre, p.ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement
40.
COPPER ALLOY ASSEMBLY AND PRODUCTION METHOD THEREFOR
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
NGK INSULATORS, LTD. (Japon)
Inventeur(s)
Takakuwa, Osamu
Matsunaga, Hisao
Ishikawa, Takahiro
Uchiyama, Hiromitsu
Sakakibara, Masato
Akaiwa, Masaaki
Abrégé
There is provided a copper alloy bonded body composed of a plurality of members made of an age-hardenable copper alloy, the members diffusion-bonded to one another. The copper alloy bonded body has undergone solution annealing and an aging treatment, the content of beryllium in the age-hardenable copper alloy is 0.7% by weight or less, and (i) a bonding interface between the members has disappeared and/or (ii) a bonding interface between the members remains, and an oxide film at the bonding interface has a thickness of 0 nm or more and 5.0 nm or less.
C22C 9/06 - Alliages à base de cuivre avec le nickel ou le cobalt comme second constituant majeur
C22F 1/02 - Modification de la structure physique des métaux ou alliages non ferreux par traitement thermique ou par travail à chaud ou à froid en atmosphère neutre ou contrôlée ou dans le vide
C22F 1/00 - Modification de la structure physique des métaux ou alliages non ferreux par traitement thermique ou par travail à chaud ou à froid
B23K 20/02 - Soudage non électrique par percussion ou par une autre forme de pression, avec ou sans chauffage, p.ex. revêtement ou placage au moyen d'une presse
C22F 1/08 - Modification de la structure physique des métaux ou alliages non ferreux par traitement thermique ou par travail à chaud ou à froid du cuivre ou de ses alliages
B32B 15/01 - Produits stratifiés composés essentiellement de métal toutes les couches étant composées exclusivement de métal
41.
DISEASE STATE ASSESSMENT KIT FOR RETT SYNDROME AND USE OF GENE CONTAINED IN MITOCHONDRIAL GENOME AS BIOMARKER
INSTITUTE OF RHEOLOGICAL FUNCTION OF FOOD CO., LTD. (Japon)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Fujino Takehiko
Mawatari Shiro
Honsho Masanori
Abrégé
This disease state assessment kit for Rett syndrome comprises a reagent for detecting a gene contained in the mitochondrial genome in a sample collected from a subject.
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
MEIJI CO., LTD. (Japon)
Inventeur(s)
Tachibana Hirofumi
Lin Jerchyuan
Abrégé
The purpose of the present invention is to provide a novel composition for improving brain function and a novel composition for promoting the production of brain-derived neurotrophic factor (BDNF). The present invention provides a composition for maintaining and/or improving brain function that contains isovaleraldehyde as an active ingredient. The present invention also provides a composition for promoting the production of brain-derived neurotrophic factor (BDNF) that contains isovaleraldehyde as an active ingredient. The aforesaid compositions are preferably food compositions, feed compositions or pharmaceutical compositions.
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/12 - Gènes codant pour des protéines animales
43.
BLAST STATE EVALUATION DEVICE, BLAST STATE EVALUATION SYSTEM, BLAST STATE EVALUATION METHOD, AND BLAST STATE EVALUATION PROGRAM
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Shinoda Takeshi
Tanaka Takashi
Abrégé
This blast state evaluation device evaluates the blast rate after a blast treatment on a surface to be examined of a structure, the device including: an irradiation unit 11 that irradiates the surface to be examined with measurement light; a detection unit 12 that detects reflected light from the surface to be examined that has been irradiated with the measurement light; and an evaluation unit 22 serving as an analysis unit that estimates the blast rate on the surface to be examined on the basis of the intensity of light of a specific wavelength included in the reflected light detected at the detection unit 12.
G01N 21/27 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
G01B 11/30 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour mesurer la rugosité ou l'irrégularité des surfaces
44.
METHOD FOR INHIBITING HYDROGEN EMBRITTLEMENT OF ALUMINUM ALLOY MATERIAL, AND HYDROGEN EMBRITTLEMENT INHIBITOR
C22C 21/10 - Alliages à base d'aluminium avec le zinc comme second constituant majeur
C22F 1/00 - Modification de la structure physique des métaux ou alliages non ferreux par traitement thermique ou par travail à chaud ou à froid
C22F 1/04 - Modification de la structure physique des métaux ou alliages non ferreux par traitement thermique ou par travail à chaud ou à froid de l'aluminium ou de ses alliages
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
KYOEISHA CHEMICAL CO., LTD. (Japon)
Inventeur(s)
Takashima, Yoshinori
Park, Junsu
Tanaka, Masaru
Ueda, Tomoya
Araki, Kumiko
Takenaka, Naomi
Kure, Bunsho
Abrégé
The present invention improves the physical properties of a polymer that includes an alkoxy alkyl (meth)acrylate as a principal structural unit to achieve a polymer that has physical properties that are very similar to a biological substance. The present invention provides a copolymer that includes as structural units (A) a hydroxy alkyl (meth)acrylate and/or an alkoxy alkyl (meth)acrylate and (B) a monomer that has a host group.
C08F 220/26 - Esters contenant de l'oxygène en plus de l'oxygène de la fonction carboxyle
C08F 220/28 - Esters contenant de l'oxygène en plus de l'oxygène de la fonction carboxyle ne contenant pas de cycles aromatiques dans la partie alcool
C08F 220/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
C08L 33/14 - Homopolymères ou copolymères des esters d'esters contenant des atomes d'halogène, d'azote, de soufre ou d'oxygène en plus de l'oxygène du radical carboxyle
C08L 33/26 - Homopolymères ou copolymères de l'acrylamide ou de la méthacrylamide
A61L 27/16 - Matériaux macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Yamamoto, Hiroaki
Ooe, Kenichi
Katakura, Yoshinori
Abrégé
An object of the present disclosure is at least to provide a technique for enhancing expression of a NAMPT gene. The object is achieved by a composition for enhancing NAMPT gene expression, the composition containing an equol compound as an active ingredient.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Ishibashi Yushi
Suriyasak Chetphilin
Hamaoka Norimitsu
Abrégé
The present invention addresses the problem of clarifying the relation between environmental stress and seed quality and improving the yield and quality of a crop seed by a new method different from conventional gene engineering methods. Provided are: a plant seed having a promotor in which the methylation level of any gene selected from the group consisting of gene SLB1, gene Hd1, gene AGPS2b, gene GBSSI, gene SuSy2, gene AMy1A, and gene Amy3D is effectively controlled, and a product of the plant seed; and a harvest obtained therefrom and a processed product of the harvest. Also provided is a method for producing a plant seed having useful characteristics, the production method involving: a step for culturing a first generation plant under environmental stress; and a step for obtaining, from the cultured plant or an offspring thereof, a seed memorizing the environmental stress.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SOKEN CHEMICAL & ENGINEERING CO.,LTD. (Japon)
Inventeur(s)
Tanaka Masaru
Kobayashi Shingo
Shimizu Seiichi
Goto Shuichi
Takahashi Takanori
Abrégé
Provided is a polymer composition that exhibits sufficient biocompatibility and is capable of suppressing the elastic modulus, which is the source of elastic force that is generated by deformation. Provided is a polymer composition containing a polymer that has a (meth)acrylate backbone and that contains, at the side chain segment relative to this backbone, repeating units having a propylene glycol structure in which the number of repetitions is at least four.
Kyushu University, National University Corporation (Japon)
Inventeur(s)
Noda, Tetsuji
Onaga, Tomotsune
Katakura, Yoshinori
Abrégé
The object of the present invention is to provide an inexpensive and effective sirtuin activator derived from natural products.
The object of the present invention is to provide an inexpensive and effective sirtuin activator derived from natural products.
The problem can be solved by a sirtuin activator comprising β-alanine or a salt thereof, or a composition for activating sirtuin comprising the sirtuin activator as an active ingredient, of the present invention.
A61K 31/197 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p.ex. acide gamma-aminobutyrique (GABA), bêta-alanine, acide epsilon-aminocaproïque, acide pantothénique
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
50.
THERMALLY ACTIVATED DELAYED FLUORESCENCE MATERIAL AND ORGANIC ELECTROLUMINESCENT ELEMENT
NIPPON STEEL Chemical & Material Co., Ltd. (Japon)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Tada, Masashi
Sagara, Yuta
Kawada, Atsushi
Yasuda, Takuma
Park, In Seob
Kim, Jong Uk
Shikita, So
Abrégé
Provided is a thermally activated delayed fluorescence organic EL device having high emission efficiency and a long lifetime. An organic EL device comprising light emitting layers between an anode and a cathode opposite to each other; wherein at least one of the light emitting layers contains, as a thermally activated delayed fluorescence material, a compound in which a boron-containing electron acceptor backbone is linked with an electron donor backbone having a specific fused ring structure; and the compound is represented by the following general formula (1) where X1 is O or S.
Provided is a thermally activated delayed fluorescence organic EL device having high emission efficiency and a long lifetime. An organic EL device comprising light emitting layers between an anode and a cathode opposite to each other; wherein at least one of the light emitting layers contains, as a thermally activated delayed fluorescence material, a compound in which a boron-containing electron acceptor backbone is linked with an electron donor backbone having a specific fused ring structure; and the compound is represented by the following general formula (1) where X1 is O or S.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Fujikawa Shigenori
Selyanchyn Roman
Shimizu Kenichi
Abrégé
This carbon dioxide separation/conversion device comprises: one or more separation units (10) for separating carbon dioxide from a carbon dioxide-containing gas to obtain a carbon dioxide-enriched gas; a reaction unit (30) that comprises a catalyst for absorbing and converting carbon dioxide in the carbon dioxide-enriched gas, causes absorption of carbon dioxide in the carbon dioxide-enriched gas by the catalyst, and obtains a post-conversion gas including a conversion product from the carbon dioxide absorbed by the catalyst and hydrogen; and a hydrogen delivery unit (40) that delivers hydrogen to the reaction unit (30), wherein the separation unit (10) comprises one or more separation membrane modules including a separation membrane that separates carbon dioxide from a gas containing carbon dioxide, and a separation membrane module connection unit, which is connected to each separation membrane module and includes a carbon dioxide delivery port through which the carbon dioxide-enriched gas is discharged.
B01D 53/14 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
B01D 53/22 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
B01D 71/70 - Polymères contenant, dans la chaîne principale, uniquement du silicium, avec ou sans soufre, azote, oxygène ou carbone
C07C 1/12 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir d'oxydes de carbone à partir d'anhydride carbonique avec de l'hydrogène
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Meno Chikara
Nii Takenobu
Abrégé
The present invention provides an embryo culture method. More specifically, the invention includes culturing an embryo (especially pre-implantation) on a dish having, on the surface thereof, an extracellular matrix layer having a sufficient thickness. The invention enables, for example, development of an embryo into a post-implantation embryo.
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Inada Keita
Watanabe Takayuki
Tanaka Manabu
Matsui Kazuki
Abrégé
33-R [where R is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, or an organic group (which is not a hydrocarbon group)] around the electrical-discharge region in the plasma device; and continuously discharging gases from the plasma device.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Yamauchi Miho
Anzai Akihiko
Yoshizawa Akina
Higashi Manabu
Abrégé
22, a hydrogen carbonate, and a carbonate. The membrane-electrode assembly (10) comprises: an electrolytic membrane (13); and a cathode catalyst layer (12) that is provided on the electrolytic membrane (13) and that contains a catalyst. In a state in which the cathode electrode (11) and the cathode catalyst layer (12) are in contact with each other, a cathode contact area, which is an area where the cathode catalyst layer (12) is exposed and where the cathode electrode (11) and the material fluid are not in contact with each other or the cathode electrode (11) and the material fluid are in contact with each other, is smaller than a catalyst contact area, which is an area where the material fluid and an exposure portion in which the cathode catalyst layer is exposed are in contact with each other.
C25B 9/00 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Éléments de structure des cellules; Assemblages d'éléments de structure, p.ex. assemblages d'électrode-diaphragme; Caractéristiques des cellules relatives aux procédés
C25B 9/23 - Cellules comprenant des électrodes fixes de dimensions stables; Assemblages de leurs éléments de structure avec des diaphragmes comprenant des membranes échangeuses d'ions dans ou sur lesquelles est incrusté du matériau pour électrode
C25B 11/037 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par la configuration ou la forme Électrodes constituées de particules
55.
METHOD AND APPARATUS FOR PRODUCING SYNTHESIS GAS CONTAINING CARBON MONOXIDE
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Attri Pankaj
Koga Kazunori
Okumura Takamasa
Shiratani Masaharu
Abrégé
The present invention provides a method which comprises: a carbon dioxide application step in which carbon dioxide is applied to an ionic liquid; and a plasma irradiation step in which carbon dioxide is converted into carbon monoxide by irradiating the ionic liquid, to which carbon dioxide has been applied, with a plasma.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Yanai, Nobuhiro
Kimizuka, Nobuo
Harada, Naoyuki
Sasaki, Yoichi
Watanabe, Yuya
Mai, Bac Lam
Abrégé
A photon upconversion composition containing a naphthalene compound substituted with a substituent containing at least one selected from the group consisting of an alkynyl group, a substituted silyl group, a benzene ring, an heteroaromatic ring, a cyano group and a halogen atom can efficiently convert an excitation light into a UV light at a low excitation light intensity.
C07F 7/08 - Composés comportant une ou plusieurs liaisons C—Si
C07C 15/58 - Hydrocarbures cycliques ne contenant que des cycles aromatiques à six chaînons en tant que partie cyclique substitués par des radicaux hydrocarbonés non saturés polycycliques condensés contenant deux cycles
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Ishihara, Tatsumi
Okuda, Norikazu
Kimizuka, Ken-Ichi
Tasaki, Ken
Abrégé
It is desired to develop a method of producing hydrogen peroxide, which is capable of producing hydrogen peroxide with high production efficiency. According to the present invention, provided is a palladium-containing composition comprising palladium particles and a coating agent that coats the surface of the palladium particles, wherein a compound having an O═X structure (wherein X represents any of a phosphorus atom, a sulfur atom, and a carbon atom) is comprised as the coating agent.
B01J 31/28 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant en outre des composés métalliques inorganiques non prévus dans les groupes du groupe du platine, du cuivre ou du groupe du fer
C01B 15/029 - Préparation à partir de l'hydrogène et de l'oxygène
B01J 35/02 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides
KYUSHU UNIVERSITY,NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Mori,shoji
Hisano,tsutomu
Takata,yasuyuki
Abrégé
Provided are a cooling device and a cooler that is capable of causing boiling at a low superheat by suppressing an increase in a boiling starting point. The cooler uses a boiling method for cooling a heating element, and comprises: a container that accommodates a working fluid; a cooling member that is provided inside the container so as to face the surface of the heating element and that is composed of a porous body; and at least one metal fine wire or a metal thin film that is provided between the surface of the heating element and the cooling member, and is configured so as to be able to be heated.
F28F 13/02 - Dispositions pour modifier le transfert de chaleur, p.ex. accroissement, diminution en influençant la couche limite
H01L 23/427 - Refroidissement par changement d'état, p.ex. caloducs
F28D 15/02 - Appareils échangeurs de chaleur dans lesquels l'agent intermédiaire de transfert de chaleur en tubes fermés passe dans ou à travers les parois des canalisations dans lesquels l'agent se condense et s'évapore, p.ex. tubes caloporteurs
H05K 7/20 - Modifications en vue de faciliter la réfrigération, l'aération ou le chauffage
59.
COOLING MEMBER, COOLER, COOLING DEVICE, AND COOLING MEMBER MANUFACTURING METHOD
KYUSHU UNIVERSITY,NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Mori,shoji
Sekiguchi,tadashi
Hayashida,yuya
Abrégé
Provided are a cooling member having a favorable cooling effect, a cooler, a cooling device, and a cooling member manufacturing method. The cooling member comprises integrally formed electrolytic metal foils constituted by a double-layer porous material, each layer having different mean pore sizes.
H01L 23/427 - Refroidissement par changement d'état, p.ex. caloducs
F28D 15/02 - Appareils échangeurs de chaleur dans lesquels l'agent intermédiaire de transfert de chaleur en tubes fermés passe dans ou à travers les parois des canalisations dans lesquels l'agent se condense et s'évapore, p.ex. tubes caloporteurs
F28D 15/04 - Appareils échangeurs de chaleur dans lesquels l'agent intermédiaire de transfert de chaleur en tubes fermés passe dans ou à travers les parois des canalisations dans lesquels l'agent se condense et s'évapore, p.ex. tubes caloporteurs avec des tubes ayant une structure capillaire
H05K 7/20 - Modifications en vue de faciliter la réfrigération, l'aération ou le chauffage
60.
PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF FIBROTIC DISEASE
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Nakaya, Michio
Abrégé
This pharmaceutical composition for treatment or prevention of fibrotic disease contains nucleic acid that inhibits the expression of mRNA encoding P4HA3. The fibrotic disease may be at least one disease selected from the group consisting of fibrosis, cirrhosis, renal failure, myocardial infarction, and cancer. The present invention provides a method for preventing or treating fibrotic disease, the method including administering an effective amount of the pharmaceutical composition according to the present invention to a subject who has, or is at risk of contracting, fibrotic disease.
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 9/04 - Agents inotropes, c. à d. stimulants de la contraction cardiaque; Médicaments pour le traitement de l'insuffisance cardiaque
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Matsuda Osamu
Ogawa Kenichi
Abrégé
Provided is a measurement device for measuring the mass or mass distribution of particles including organic material, said measurement device comprising: a supply means for supplying particles; an irradiation means for irradiating the particles with near infrared light; an imaging means for acquiring data pertaining to the reflectivity of near infrared light reflected from the particles at an m number of specific wavelengths; and a calculation means for calculating the mass of the particles on the basis of the data pertaining to the reflectivity of the near infrared light at the m number of specific wavelengths. Also provided is a measurement method for measuring the mass or mass distribution of particles including organic material, said method comprising the following steps: (a) supplying particles to a measurement device; (b) irradiating the particles with near infrared light and acquiring data pertaining to the reflectivity of near infrared light at an m number of specific wavelengths; and (c) calculating the mass of the particles on the basis of the acquired data.
G01N 15/00 - Recherche de caractéristiques de particules; Recherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux
G01G 9/00 - Méthodes ou appareils pour la détermination du poids, non prévus dans les groupes
G01G 17/00 - Appareils ou méthodes pour peser un produit ayant une forme ou des propriétés particulières
G01N 21/27 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
G01N 21/3563 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de solides; Préparation des échantillons à cet effet
G01N 21/359 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant la lumière de l'infrarouge proche
63.
ANTICANCER DRUG AND ANTICANCER DRUG SCREENING METHOD
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
64.
TECHNICAL ELEMENT ANALYSIS METHOD, LEARNING METHOD, TECHNICAL ELEMENT ANALYSIS SYSTEM, AND PROGRAM
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Chiwata, Nobuhiko
Mine, Tsunenori
Sakai, Toshihiko
Abrégé
A computer 30 receives, for a limited document group 4B as a document group of a specific technical field, a setting operation for an annotation in which a main intrinsic representation tag T1 and a sub intrinsic representation tag T2 are associated with each other, generates annotation data 5 (training data), finely tunes a pre-learning model 6, which is learned in advance by using a large document group 3, according to the annotation data 5, and generates an intrinsic representation extraction model 8 for extracting information about intrinsic representations from documents. Furthermore, the computer 30 receives a target document 2 as an analysis target and extracts information about intrinsic representations from the target document 2 by using the specific representation extraction model 8.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Tanaka, Masaru
Taniguchi, Shota
Nakamura, Kenichi
Abrégé
This medical coating agent comprises a polymer including a structural unit (A) derived from an ethylenic unsaturated monomer having a urea bond. The polymer contained in the medical coating agent satisfies Condition (i) in a case where a polymer water-holding state when the peak top of heat absorption due to the melting of ice appears at 0°C is defined as a water saturation state in a DSC curve obtained by letting the polymer absorb water and then heating the polymer at a rate of 5°C/min using a differential scanning calorimeter. Condition (i): The intermediate water amount in the water saturation state is not less than 3.0 mass% with respect to the entire amount of the polymer in the water saturation state.
NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (Japon)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Tada Masashi
Sagara Yuta
Kitera Sayuri
Yasuda Takuma
Min Hyukgi
Abrégé
Provided are a luminescent material, and an organic EL element using the luminescent material and having a high luminous efficiency and a long lifespan. Provided is an organic EL element including a luminescent layer between an anode and a cathode that face one another, wherein a compound, which serves as a luminescent dopant and in which a boron atom and a scaffold having a specific structure are combined, is included in at least one luminescent layer. The compound is represented by general formula (1) or general formula (2).
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Matsueda Hironobu
Sakata Hiroshi
Otsuki Shujiro
Yamamoto Eiji
Tokunaga Makoto
Murayama Haruno
Takaki Yuta
Kawai Yasutaka
Takakura Kei
Kimura Moemi
Abrégé
A method for producing an olefin sulfide according to the present invention enables the achievement of a dialkyl polysulfide (A) by reacting an olefin compound (a) represented by formula (1) R1R2C=CHR3(wherein each of R1and R2represents an alkyl group; R3represents a hydrogen atom or an alkyl group; and the total number of carbon atoms in R1, R2and R3 is 2 to 20) and sulfur with each other in the presence of hydrogen.
C07C 321/14 - Sulfures, hydropolysulfures ou polysulfures ayant des groupes thio liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kang, Dongchon
Uchiumi, Takeshi
Igami, Ko
Abrégé
Substances present in urinary microvesicles of bladder cancer patients are identified to thereby construct a method of assisting in early and accurate diagnosis of bladder cancer. In the assistant method, microvesicles are enriched, and whether or not the subject patient has bladder cancer is determined depending on the amount of a marker protein present in the microvesicles.
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
69.
METAL-CROSSLINKABLE POLYMER COMPOSITION, METAL-CROSSLINKED POLYMERIC MATERIAL, METAL COMPONENT, AND WIRING HARNESS
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Oshiumi, Naoyuki
Hosokawa, Takehiro
Mizoguchi, Makoto
Abrégé
A metal-crosslinkable polymer composition and a metal crosslinked polymeric material having excellent curing rate and storage stability, and a metal member and a wiring harness to which the metal-crosslinkable polymer composition and the metal crosslinked polymeric material are applied. The metal-crosslinkable polymer composition includes an ingredient A which releases a metal ion when heated, and an ingredient B includes an organic polymer having a substituent group capable of forming an ionic bond with the metal ion released from the ingredient A. The metal-crosslinked polymeric material includes a crosslinked product of the metal-crosslinkable polymer composition. The metal member has a metal base member and a coating member covering a surface of the metal base member, where the coating member includes the metal-crosslinked polymeric material. The wiring harness includes the metal-crosslinked polymeric material.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kamihira Masamichi
Kawabe Yoshinori
Akiyama Kyosuke
Abrégé
The purpose of the present invention is to provide a heparin-like substance having a high biological activity (anticoagulant activity) as heparin. Provided is a method for producing a heparin-like substance, the method including a step for culturing an animal cell having, introduced therein, the below-mentioned polynucleotides to produce a supernatant containing the heparin-like substance. A polynucleotide encoding bifunctional heparan sulfate N-deacetylase/N-sulfotransferase (NDST2); a polynucleotide encoding heparan sulfate glucosamine 3-sulfotransferase 1 (Hs3st1); a polynucleotide encoding an extracellular domain of syndecan (SDC); and a polynucleotide encoding 6-O-sulfotransferase.
C07K 14/78 - Peptides du tissu connectif, p.ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid (CIG)
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 15/12 - Gènes codant pour des protéines animales
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p.ex. glutathion
71.
MEMBRANE PROTEIN ANALYSIS SUBSTRATE, METHOD OF PRODUCING MEMBRANE PROTEIN ANALYSIS SUBSTRATE, METHOD OF ANALYZING MEMBRANE PROTEIN AND MEMBRANE PROTEIN ANALYSIS GRID
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Shimada, Atsushi
Abrégé
A membrane protein analysis substrate including an electron microscope grid having a plurality of through-holes; a lipid bilayer membrane that is provided to cover at least one of the plurality of through-holes; and membrane proteins that are retained in a part planarly overlapping the through-holes of the lipid bilayer membrane, wherein the lipid bilayer membrane has a lipid monolayer, and wherein the lipid monolayer is larger than the through hole in a plan view, adheres to the grid, and constitutes a part of the lipid bilayer membrane,
G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
72.
METHOD FOR LEACHING NICKEL FROM NICKEL ORE AND METHOD FOR PRODUCING NICKEL SULFATE
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
TOYOTA TSUSHO CORPORATION (Japon)
TOYOTA JIDOSHA KABUSHIKI KAISHA (Japon)
Inventeur(s)
Yamamoto, Yuji
Goto, Masahiro
Hanada, Takafumi
Moriyama, Takeru
Ohsawa, Ryosuke
Abrégé
Provided is a method for leaching nickel from a nickel oxide ore that enables a nickel sulfate production method which is easily carried out with a small amount of waste generation. The method for leaching nickel into an organic phase disclosed here includes the step of bringing a nickel ore into contact with an organic phase. The organic phase contains a hydrophobic deep eutectic solvent including a hydrogen bond donor and a hydrogen bond acceptor, and an organic acid. The hydrogen bond donor is an acidic hydrogen bond donor. The organic acid is a strong acid.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
MITSUI NORIN CO., LTD. (Japon)
Inventeur(s)
Tachibana Hirofumi
Takagaki Akiko
Abrégé
One of the problems addressed by the present invention is to provide a cancer-cell proliferation inhibitor that contains a compound that is derived from a food component and that is highly safe. The description of the present application discloses a cancer-cell proliferation inhibitor that contains an immune checkpoint inhibitor and at least one of 5-(3,5-dihydroxyphenyl)-γ-valerolactone represented by formula (I), a salt of said compound, and a conjugate of said compound.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORP. (Japon)
Inventeur(s)
Fujiura, Kento
Ueda, Tomoya
Tanaka, Masaru
Abrégé
[Problem to be Solved] To provide a polymer material having cancer cell adhesion properties while having biocompatibility.
[Problem to be Solved] To provide a polymer material having cancer cell adhesion properties while having biocompatibility.
[Means to Solve the Problem] A composition for cancer cell adhesion according to the present invention comprises a biocompatible copolymer comprising:
at least one repeating unit (A) represented by the following formula (1):
wherein
R1 represents a methyl group or an ethyl group; and
at least one repeating unit (B) represented by the following formula (2):
wherein
R2 represents an aliphatic hydrocarbon group.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SENTAN PHARMA INC. (Japon)
Inventeur(s)
Murakami, Yusuke
Sonoda, Koh-Hei
Ikeda, Yasuhiro
Koga, Tsuneyuki
Matsuo, Takeru
Eguchi, Yojiro
Furuie, Hironobu
Abrégé
This invention includes, e.g., a pharmaceutical composition serving to treat retinitis pigmentosa and containing nanoparticles in which statin is encapsulated.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SHIN-ETSU CHEMICAL CO., LTD. (Japon)
Inventeur(s)
Nagashima, Hideo
Sanagawa, Atsushi
Kawabata, Shoma
Noda, Daisuke
Sakuta, Koji
Abrégé
Provided is a catalyst which comprises a compound represented by formula (1) and which exhibits activity for at least one type of reaction selected from among hydrosilylation reaction or hydrogenation reaction with respect to an aliphatic unsaturated bond and hydrosilane reduction reaction with respect to a carbon-oxygen unsaturated bond or a carbon-nitrogen unsaturated bond. Formula (1): Mn(Lm) {M represents Fe, Co, or Ni having an oxidation number of 0, L represents an isocyanide ligand represented by formula (2), n denotes an integer of 1-8, and m denotes an integer of 2-12. Formula (2): (CN)x—R1 (R1 represents a mono- to trivalent-organic group having 1-30 carbon atoms, optionally being substituted by a halogen atom, and optionally having interposed therein one or more atoms selected from among O, N, S, and Si; and x denotes an integer of 1-3)}.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
KOALA TECH INC. (Japon)
Inventeur(s)
Adachi Chihaya
Park Hyunsuk
Bencheikh Fatima
Komatsu Ryutaro
Fujihara Takashi
Abrégé
An organic semiconductor laser device with a supercell structure composed of a first short-pitch periodic structure with length WS1, a long-pitch periodic structure with length WL and a second short-pitch periodic structure with length WS2 is improved by lengthening (WS1 + WS2), shortening WL, lengthening (WS1 + WL + WS2), or repeating the supercell structure.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Tsukahara, Shigehiro
Matsumoto, Takashi
Shiota, Masaki
Eto, Masatoshi
Kang, Dongchon
Kodama, Keisuke
Abrégé
The present invention provides a primer set for detecting the presence of bladder cancer in a specimen, said primer set containing a pair of primers that are oligonucleotides targeting a PLEKHS1 promoter mutation and having a length of 16-21 bases inclusive, and one or more pairs of primers targeting a TERT promoter mutation.
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
79.
ELECTRODE MATERIAL, METHOD FOR PRODUCING SAME, AND ELECTRODE USING SAME, MEMBRANE ELECTRODE ASSEMBLY, AND SOLID-STATE POLYMER FUEL CELL
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Noda Zhiyun
Nishiizumi Ryosuke
Inoue Yusuke
Matsuda Junko
Nishihara Masamichi
Hayashi Akari
Sasaki Kazunari
Abrégé
Provided is an electrode material for providing a fuel cell electrode having superior electrode performance and durability. This electrode material is the following electrode material (A) or electrode material (B). Electrode material (A): An electrode material including a porous composite carrier composed of a carbon carrier made of mesoporous carbon and an electron conductive oxide fixed to, among the pore inner surfaces and pore outer surfaces of the mesoporous carbon, at least the pore inner surfaces of the mesoporous carbon, and including electrode catalyst particles carried on the porous composite carrier, wherein some or all of the electrode catalyst particles are carried on the pore inner surfaces of the mesoporous carbon via the electron conductive oxide. Electrode material (B): An electrode material including a carbon carrier made of mesoporous carbon, and an electrode catalyst composite fixed to, among the pore inner surfaces and pore outer surfaces of the mesoporous carbon, at least the pore inner surfaces of the mesoporous carbon, wherein the electrode catalyst composite includes electrode catalyst particles and an electron conductive oxide, and the electron conductive oxide is present so as to fill the gaps between the electrode catalyst particles.
H01M 4/86 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes inertes ayant une activité catalytique, p.ex. pour piles à combustible
H01M 4/90 - Emploi de matériau catalytique spécifié
H01M 8/10 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides
80.
POLYMER, CROSSLINKED OBJECT, ELECTRIC WIRE, WIRE HARNESS, METHOD FOR PRODUCING POLYMER, AND METHOD FOR PRODUCING CROSSLINKED OBJECT
C08G 65/26 - Composés macromoléculaires obtenus par des réactions créant une liaison éther dans la chaîne principale de la macromolécule à partir d'éthers cycliques par ouverture d'un hétérocycle à partir d'éthers cycliques et d'autres composés
C08G 65/10 - Oxiranes saturés caractérisés par les catalyseurs utilisés
H01B 7/00 - Conducteurs ou câbles isolés caractérisés par la forme
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SUMITOMO METAL MINING CO., LTD. (Japon)
Inventeur(s)
Hirajima Tsuyoshi
Miki Hajime
Suyantara Gde Pandhe Wisnu
Sasaki Keiko
Tanaka Yoshiyuki
Takida Eri
Abrégé
Provided is an ore dressing method that can obtain a low-arsenic-grade concentrate from a high-arsenic-grade starting material. The ore dressing method has: a repulping step for obtaining a mineral slurry by adding water to a starting material that contains an arsenic-free sulfide mineral, i.e., a sulfide mineral that does not contain arsenic, and an arsenic-containing sulfide mineral, i.e., a copper sulfide mineral that contains arsenic; a pH adjustment step for adjusting the pH of the liquid phase of the mineral slurry to at least 10; a conditioning step for adding an oxidizing agent and an alkali metal xanthate to the mineral slurry; and a flotation step for carrying out flotation using the mineral slurry to effect separation of the starting material into: a floating ore that has a higher grade of arsenic-free sulfide mineral than the starting material, and a sedimented ore that has a higher grade of arsenic-containing sulfide mineral than the starting material. The starting material contains 4.4-5.8 weight parts of arsenic per 100 weight parts of copper.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
OSAKA SODA CO., LTD. (Japon)
Inventeur(s)
Katakura, Yoshinori
Nishikawa Kouji
Idogaki, Hideaki
Tokimoto, Yuji
Abrégé
The purpose of the present invention is to provide a novel material that promotes the production of collagen and/or hyaluronic acid and/or activates human epidermal keratinocytes. A lactic acid bacterium belonging to the genus Fructobacillus, a culture of the lactic acid bacterium, a culture supernatant of the lactic acid bacterium, and/or an extract of the lactic acid bacterium are useful as an active ingredient in a collagen production promotor, a hyaluronic acid production promoter, and an epidermal keratinocyte activator.
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p.ex. à base de protozoaires ou de bactéries
A23L 33/135 - Bactéries ou leurs dérivés, p.ex. probiotiques
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p.ex. arthrites, arthroses
A61P 19/04 - Médicaments pour le traitement des troubles du squelette des troubles non-spécifiques du tissu conjonctif
A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p.ex. rachitisme, maladie de Paget de l'ostéoporose
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Nishimura Takuma
Shioji Yudai
Tanabe Shichidai
Nishiura Masahito
Kobayashi Shingo
Tanaka Masaru
Abrégé
Provided is a medical device that can achieve both of biocompatibility and physical properties and contains a polyurethane resin elastomer. The medical device according to an embodiment includes a polyurethane resin elastomer and water contained in the polyurethane resin elastomer. The polyurethane resin elastomer contains polyethylene glycol and a polyisocyanate as constituents thereof, in which the polyethylene glycol has a number average molecular weight of 200 to 2200 inclusive, and the amount of the polyethylene glycol relative to 100% by mass of the constituents of the polyurethane resin elastomer is 1% by mass or more and less than 50% by mass.
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 29/06 - Matériaux macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 31/06 - Matériaux macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
C08G 18/28 - Polymérisats d'isocyanates ou d'isothiocyanates avec des composés contenant des hydrogènes actifs caractérisés par l'emploi de composés spécifiés contenant un hydrogène actif
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Otsu Masato
Arita Kazuo
Sato Eriko
Abrégé
According to the present invention, an epoxy resin composition that is capable of combining flexibility, toughness, and adhesiveness and that can be dismantled easily by heating, a cured product thereof, and a laminate can be provided. The epoxy resin composition of the present invention contains an epoxy resin (A) having an epoxy equivalent of 500-10,000 g/eq, an epoxy resin (B) having an epoxy equivalent of 100-300 g/eq, and a compound (C) having an anthracene dimer skeleton. The epoxy resin (A) is represented by general formula (1), and the compound (C) has two or more epoxy group-containing groups or two or more curable group-containing groups.
C08G 59/40 - Macromolécules obtenues par polymérisation à partir de composés contenant plusieurs groupes époxyde par molécule en utilisant des agents de durcissement ou des catalyseurs qui réagissent avec les groupes époxyde caractérisées par les agents de durcissement utilisés
B32B 7/12 - Liaison entre couches utilisant des adhésifs interposés ou des matériaux interposés ayant des propriétés adhésives
B32B 27/38 - Produits stratifiés composés essentiellement de résine synthétique comprenant des résines époxy
C08G 59/20 - Macromolécules obtenues par polymérisation à partir de composés contenant plusieurs groupes époxyde par molécule en utilisant des agents de durcissement ou des catalyseurs qui réagissent avec les groupes époxyde caractérisées par les composés époxydés utilisés
C09J 163/00 - Adhésifs à base de résines époxy; Adhésifs à base de dérivés des résines époxy
87.
ANTITHROMBOTIC CELL ADHESION SHEET AND MEDICAL DEVICE WITH SHEET
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Sugasaki, Atsushi
Yamamoto, Yosuke
Shigenoi, Yuta
Tanaka, Masaru
Kobayashi, Shingo
Abrégé
A first object of the present invention is to provide an antithrombotic cell adhesion sheet having excellent antithrombotic properties and cell adhesion properties. In addition, a second object of the present invention is to provide a medical device with a sheet using the antithrombotic cell adhesion sheet.
A first object of the present invention is to provide an antithrombotic cell adhesion sheet having excellent antithrombotic properties and cell adhesion properties. In addition, a second object of the present invention is to provide a medical device with a sheet using the antithrombotic cell adhesion sheet.
The antithrombotic cell adhesion sheet of the present invention is a sheet formed b using a compound represented by General Formula (1).
A first object of the present invention is to provide an antithrombotic cell adhesion sheet having excellent antithrombotic properties and cell adhesion properties. In addition, a second object of the present invention is to provide a medical device with a sheet using the antithrombotic cell adhesion sheet.
The antithrombotic cell adhesion sheet of the present invention is a sheet formed b using a compound represented by General Formula (1).
A first object of the present invention is to provide an antithrombotic cell adhesion sheet having excellent antithrombotic properties and cell adhesion properties. In addition, a second object of the present invention is to provide a medical device with a sheet using the antithrombotic cell adhesion sheet.
The antithrombotic cell adhesion sheet of the present invention is a sheet formed b using a compound represented by General Formula (1).
In General Formula (1), R1 and R4 each independently represent a hydrogen atom or a methyl group. R2 and R3 each independently represent —CH2CH(RA1)CH2—. p and r represent 1. q represents 0 or 1. m and n each independently represent an integer of 2 to 6. RA1 represents a hydrogen atom or a methyl group.
: The invention provides a sample holder arrangement (1) comprising (i) a 5 collection chamber (100) having an interior space (101), (ii) a sample holding part (3), (iii) an inlet (110), and (iv) an outlet (120); wherein: the inlet (110) is configured for receiving a supercritical fluid (10); the outlet (120) is configured for depressurizing one or more of the interior space (101) and the sample holding part; the sample holding part (3) is detachably configured in the interior space (101); the sample holding part (3) hosts a single crystal of a 0 porous framework (20) such that the single crystal of a porous framework (20) is configured in the interior space (101); and the single crystal of the porous framework (20) is configured in fluid connection with the inlet (110).
G01N 23/20025 - Porte-échantillons ou leurs supports
B01D 15/40 - Adsorption sélective, p.ex. chromatographie caractérisée par le mécanisme de séparation utilisant un fluide supercritique comme phase mobile ou comme éluant
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Soto-Gutierrez, Alejandro
Takeishi, Kazuki
Morita, Kazutoyo
Haep, Nils
Florentino, Rodrigo Machado
Achreja, Abhinav
Nagrath, Deepak
Animasahun, Olamide
Yoshizumi, Tomoharu
Abrégé
PNPLA3PNPLA3) gene. The method can include administering to the subject glutathione (GSH) and/or a nucleic acid molecule encoding a component of the ferroptosis pathway (such as GPX4).
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
COMPOUND, RACEMATE OF SAID COMPOUND, SALT OF SAID COMPOUND OR SAID RACEMATE, COMPOSITION, ANTI-INFLAMMATORY AGENT, THERAPEUTIC AGENT FOR DEMENTIA, AND THERAPEUTIC AGENT FOR RETT SYNDROME
INSTITUTE OF RHEOLOGICAL FUNCTION OF FOOD CO., LTD. (Japon)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Fujino Takehiko
Mawatari Shiro
Okauchi Tatsuo
Niwase Shamim
Honsho Masanori
Nakashima Kinichi
Nakashima Hideyuki
Abrégé
This compound is represented by formula (I). (In formula (I), a carbon atom in the glycerol backbone may have a substituent; an oxygen atom bound to R1is represented by *; and R1 is formula (I-1) which may have a substituent.)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Nakagaki Takehiro
Nishida Noriyuki
Satoh Katsuya
Goto Masahiro
Kozaka Shuto
Abrégé
This transdermal absorption-type patch is provided with a support and an adhesive agent layer laminated on the support. The adhesive agent layer contains: a solid tacrolimus-surfactant composite in which tacrolimus is covered with a surfactant; an oil phase; and an adhesive agent. The solid tacrolimus-surfactant composite forms solid-in-oil type particles dispersed in the oil phase, and is used for the therapy of neurodegenerative disorders.
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 9/66 - Préparations en capsules, p.ex. de gélatine, de chocolat du type à libération prolongée ou discontinue contenant des émulsions, dispersions ou solutions
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07H 15/04 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide
92.
ORGANIC SOLID-STATE LASER, COMPOUND AND USE THEREOF
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
SORBONNE UNIVERSITE (France)
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (République de Corée)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
D'Aleo, Anthony
Ribierre, Jean Charles Maurice
Bencheikh, Fatima
Placide, Virginie Simone Francoise
Mamada, Masashi
Adachi, Chihaya
Abrégé
A compound represented by the formula (1) has excellent lasing properties. G1 and G2 are H or substituent; FL1 and FL2 are represented by the formula (2); BT is represented by the formula (4); and n1, n2 and m are 1 to 5.
A compound represented by the formula (1) has excellent lasing properties. G1 and G2 are H or substituent; FL1 and FL2 are represented by the formula (2); BT is represented by the formula (4); and n1, n2 and m are 1 to 5.
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07F 7/08 - Composés comportant une ou plusieurs liaisons C—Si
C07D 293/10 - Composés hétérocycliques contenant des cycles comportant des atomes d'azote et de sélénium, ou d'azote et de tellure, avec ou sans atomes d'oxygène ou de soufre, comme hétéro-atomes condensés avec des carbocycles ou avec des systèmes carbocycliques
Kyushu University, National University Corporation (Japon)
Inventeur(s)
Goto, Masahiro
Abrégé
An ionic liquid has a structure represented by the following general formula (1). In the general formula (1), R represents a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkenyl group, and at least one ethylene group comprising the alkenyl group may be substituted with a vinylene group. X+ represents a phospholipid with a cationic group.
An ionic liquid has a structure represented by the following general formula (1). In the general formula (1), R represents a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkenyl group, and at least one ethylene group comprising the alkenyl group may be substituted with a vinylene group. X+ represents a phospholipid with a cationic group.
R—COO−X+ General formula (1)
C07C 53/126 - Acides contenant au moins cinq atomes de carbone
A61K 47/24 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p.ex. cyclométhicone ou phospholipides
A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
94.
METHOD FOR PRODUCING 4-HYDROXYBUTYL ALDEHYDE, METHOD FOR PRODUCING GAMMA BUTYROLACTONE, METHOD FOR PRODUCING N-METHYL-2-PYRROLIDONE, AND COMPOUND
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Tsukamoto Shinya
Nishizawa Shohei
Kitagawa Kazuhiro
Uchida Hiroshi
Miyata Hideo
Shim Jooyoung
Yamamoto Eiji
Murayama Haruno
Tokunaga Makoto
Abrégé
The present invention provides a method for producing 4-hydroxybutyl aldehyde, the method comprising a step in which an allyl alcohol is subjected to a hydroformylation reaction together with a carbon monoxide gas and a hydrogen gas in the presence of a rhodium catalyst and a catalyst that contains at least one bidentate phosphine ligand which is selected from among formulae (1) to (3) (wherein Ar represents an optionally substituted aryl group).
C07C 45/50 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogène; Préparation des chélates de ces composés par réaction avec le monoxyde de carbone par synthèse oxo
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
NISSAN CHEMICAL CORPORATION (Japon)
Inventeur(s)
Yokoyama, Shiyoshi
Kashino, Tsubasa
Abrégé
[Problem] The present invention addresses the problem of providing: a nonlinear optically active copolymer which achieves both high glass transition temperature (Tg) and higher denseness of a nonlinear optical dye; and a nonlinear optical material which is obtained using this copolymer. [Solution] The present invention provides: a nonlinear optically active copolymer which comprises, in the same molecule thereof, at least a repeating unit A of an N-substituted maleimide skeleton represented by formula (1), and a repeating unit B represented by formula (2) and having a nonlinear optically active moiety; and an organic nonlinear optical material, a part of which is composed of this copolymer. [Chemical formula 1] (In the formula, R1represents an alkyl group, an aralkyl group, a cycloalkyl group, an aliphatic crosslinked ring group or an aryl group; R2represents a hydrogen atom or a methyl group; L1represents a divalent hydrocarbon group which may contain an ether bond and/or an ester bond; L2represents *-NHC(=O)O-, *-C(=O)NH- or *-C(=O)O- (wherein * represents a coupling end coupled to L1); and Z represents an atomic group which exhibits nonlinear optical activity.)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Matsumoto, Hiroyuki
Uemori, Takashi
Shirai, Tsuyoshi
Ishino, Yoshizumi
Ishino, Sonoko
Abrégé
The present invention provides a GG-specific mismatch endonuclease variant, a TT-specific mismatch endonuclease variant, and a GT/TG-specific mismatch endonuclease variant. The present invention also provides a mismatch specific cleaving reaction using said variant, a method for removing errors in a nucleic acid amplification reaction using a mismatch nuclease, a method for suppressing amplification of a nucleic acid having a specific base sequence during a nucleic acid amplification reaction, and a method for detecting a nucleic acid having a single base polymorphic mutation using said suppression method.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
97.
POWER CONVERSION DEVICE, CONTROL DEVICE FOR POWER CONVERSION DEVICE, AND POWER CONVERSION CONTROL METHOD
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Nishikawa, Yukihiro
Shoyama, Masahito
Hebishima, Koki
Abrégé
This power conversion device includes a control unit that controls a switching operation of a switching element of the inverter unit. The control unit is configured to switch between frequency modulation control and phase shift control, based on the output from the output converter unit, and execute. Then, the control unit is configured to, when switching between frequency modulation control and phase shift control, execute overlap control for executing the phase shift control while executing the frequency modulation control, in a predetermined switching operation range.
H02M 7/537 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif sans possibilité de réversibilité par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs, p.ex. onduleurs à impulsions à un seul commutateur
H02M 1/08 - Circuits spécialement adaptés à la production d'une tension de commande pour les dispositifs à semi-conducteurs incorporés dans des convertisseurs statiques
H02M 3/335 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu avec transformation intermédiaire en courant alternatif par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrodes de commande pour produire le courant alternatif intermédiaire utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs
98.
NEURON PROLIFERATION PROMOTING AGENT AND USE THEREOF
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Tachibana Hirofumi
Abrégé
Provided are: a neuron proliferation promoting agent containing, as an active ingredient, an inhibitor of miR-191-5p or an expression inhibitor of miR-191-5p; a prophylactic or therapeutic agent for Alzheimer's disease or depression, the agent containing the neuron proliferation promoting agent; a pharmaceutical composition for promoting neuron proliferation, the composition comprising the neuron proliferation promoting agent and a pharmaceutically acceptable carrier; and a food composition for promoting neuron proliferation, the composition comprising the neuron proliferation promoting agent.
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Makino, Yoichi
Ishino, Yoshizumi
Ishino, Sonoko
Abrégé
The present invention relates to a method for detecting a target nucleic acid, the method including cleaving a first flap of a first cleavage structure formed by a target nucleic acid, a first nucleic acid, and a second nucleic acid; cleaving a second flap of a second cleavage structure formed by a third nucleic acid, the cleaved first flap, and a fourth nucleic acid; and detecting the presence of the target nucleic acid by detecting the cleaved second flap, wherein cleaving the first flap and cleaving the second flap are carried out by cleaving the first flap and the second flap with a flap endonuclease, and the flap endonuclease has an amino acid sequence having a sequence identity of 65% or higher with an amino acid sequence of a flap endonuclease of a microbe selected from the group consisting of microbes belonging to the Order Thermococcales and microbes belonging to the Order Methanobacteriales.
NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY (Japon)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Fukui, Atsushi
Shimizu, Satoshi
Kyoda, Yuki
Yoshie, Tomohisa
Sugata, Yuito
Arakawa, Yutaka
Toyoshima, Daisuke
Abrégé
In a sensor used in an energy harvesting system, electric power generated by a solar cell module is more efficiently utilized. In a sensor (100), a resistor (3) is connected in parallel with one of a first solar cell module (1a) and a second solar cell module (1b) that have mutually different current-voltage characteristics in the same illuminance environment and in series with the other one of the first solar cell module (1a) and the second solar cell module (1b). A first voltmeter (4a) measures a voltage (V1) across the first solar cell module (1a), and a second voltmeter (4b) measures a voltage (V2) across the second solar cell module (1b). A load (6) is fed with the electric power generated by the first solar cell module (1a) and the second solar cell module (1b).